



## PRESS RELEASE

### FOR IMMEDIATE RELEASE

**Company Contact:**

Charlotte Rogers  
V.P., Business Development  
650.590.3610  
[crogers@nugeninc.com](mailto:crogers@nugeninc.com)

**Media Contacts:**

Carin Canale or Anette Breindl, Ph.D.  
Atkins + Associates for NuGEN Technologies  
858.860.0266  
[ccanale@irpr.com](mailto:ccanale@irpr.com) or [abreindl@irpr.com](mailto:abreindl@irpr.com)

### NUGEN™ TECHNOLOGIES COMPLETES SERIES C FINANCING

#### *Biotechnology pioneer Bill Rutter to join the board of directors*

SAN CARLOS, CA – August 19, 2003 – NuGEN Technologies Inc., a privately held company currently developing and commercializing products for high sensitivity nucleic acid amplification and detection, today announced the completion of a new \$7.5 million Series C round of financing. The round was led by William J. Rutter, Ph.D., George B. Rathmann, Ph.D., and James N. Wilson, each of whom has built successful technology companies and has direct experience in the diagnostic field and in the utilization of genomic information. They are joined by Sutter Hill Ventures, a premier venture capital firm based in Palo Alto, CA. Current investors also participated in the round, including Radius Venture Partners, The Band of Angels Fund, and MedCapital Ventures. Bill Rutter will join the company's board of directors as the Series C representative. The proceeds of the financing will be used to strengthen NuGEN's commercial infrastructure, and to develop the company's pipeline of products.

“When we began to evaluate our corporate development needs earlier this year, our executive team, with our Board, considered what type of financing would be the most strategic and value-enhancing for the company,” said Jan D’Alvise, President and CEO of NuGEN. “I am pleased that in this difficult environment we have been able to conclude a successful financing that includes new investors who are greatly respected within the industry, bringing years of experience with some of the best companies in biotechnology. That brain-trust is priceless. As we continue to grow and enter new markets, these advisors will be extremely valuable to NuGEN. They will be instrumental in helping us increase the visibility of our company, and will provide strategic guidance on the prioritization of new products and markets.”

“My strong interest in NuGEN is based on the belief that the analysis of genomic composition and expression is rate limiting for the advancement of both biological science and medicine, and that current methodologies are not optimal,” said Bill Rutter. “I believe that NuGEN’s technology holds significant advantages over current technology and will have a broad range of applications in both research and clinical settings.”

NuGEN’s core SPIA™ and Ribo-SPIA™ technologies are the foundation for products that can be used to accurately and confidently assess gene function by providing a simplified, robust process that can be easily automated. This coupled with the ability to analyze small samples of biological importance enables researchers to dramatically improve laboratory productivity and may enable the development of new applications for both basic research and clinical diagnostics. NuGEN currently markets the Ovation™ Nanosample RNA Amplification System for gene expression analysis on commercial and self-spotted microarrays. The company plans to launch a second Ovation™ product in early 2004 for gene expression analysis on GeneChip microarrays.

Bill Rutter is co-founder and former Chairman of Chiron Corporation, and continues to serve as a director and Chairman Emeritus of the company. He has also played a major role in the inception and development of iMetrikus, Ventria Bioscience, ReLia Biosystems and Synco Bio Partners, and continues to actively participate in the management of these companies. More recently, he founded and is the Chairman of Synergenics, LLC, a consortium of affiliated concept-stage biotech startups. George Rathmann is co-founder and former Chairman, President and CEO of Amgen and ICOS, and is currently Chairman of Nuvelo. James Wilson is the former President of Syntex, Neurex and LifeScan. Both Bill Rutter and George Rathmann are recent winners of the Biotechnology Heritage Award, which recognizes individuals who have made significant contributions to the development of biotechnology through discovery, innovation and public understanding.

**About NuGEN Technologies, Inc.**

NuGEN™ Technologies, Inc., headquartered in San Carlos, California, USA, is a privately held company focused on the development and commercialization of high sensitivity amplification and detection systems for the analysis of nucleic acids and proteins. NuGEN's mission is to develop amplification and detection systems for genomic and proteomic research. The company's proprietary technologies form the foundation for a wide range of methods and products used by researchers to prepare samples for genetic analysis. NuGEN's initial business focus is to apply its amplification and labeling technologies to gene expression analysis.

*NuGEN™, Ovation™, SPIA™ and Ribo-SPIA™ are trademarks or service marks of NuGEN™ Technologies. All other marks appearing in this press release are marks of their respective owners. Use of such marks is not intended to suggest any association or affiliation between NuGEN™ Technologies, Inc. and the entities owning those marks or their products or services.*

*This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the company's current expectations as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.*

###